Page last updated: 2024-10-16

adenine and Lymphoma, Mantle-Cell

adenine has been researched along with Lymphoma, Mantle-Cell in 208 studies

Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

Research Excerpts

ExcerptRelevanceReference
" Two weeks after the regular dose was restarted (month 3), the patient had repeated bleeding (patient was receiving aspirin for previous MI) and had to stop ibrutinib again."4.93Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. ( Ruella, M; Soubeyran, P, 2016)
" Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias."3.91Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019)
" The clinical behavior of MCL may be due to the complex pathophysiology of the disease which includes its genetic hallmark, the chromosomal translocation t(11;14) resulting in aberrant expression of cyclin D1, alteration in the DNA damage response, and constitutive activation of key anti-apoptotic pathways such as phosphatidyl-inositol 3-kinase (PI3K)/Akt and nuclear factor-kB (NF-kB)."3.78Novel targeted therapies for mantle cell lymphoma. ( Alinari, L; Baiocchi, RA; Christian, B, 2012)
" The most common grade 3 adverse events were rash/pruritis/dermatitis (19%), diarrhea (11%), hyperglycemia (11%), and hypertension (11%)."3.11Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. ( Batlevi, CL; De Frank, S; Drullinsky, P; Gerecitano, JF; Hamilton, A; Hamlin, PA; Horwitz, SM; Kumar, A; Matasar, MJ; Michaud, L; Moskowitz, A; Moskowitz, CH; Nakajima, R; Nichols, C; Rademaker, J; Salles, G; Schöder, H; Seshan, V; Stewart, CM; Straus, D; Tsui, DWY; Whiting, K; Younes, A; Zelenetz, AD, 2022)
" We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily)."3.11Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. ( Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME, 2022)
" We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients."3.11Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. ( Aymerich, M; Beà, S; Campo, E; Casanova, M; Cortés-Romera, M; de la Cruz, F; de la Fuente, A; García Sanz, R; Giné, E; González Barca, E; González-López, TJ; Jiménez Ubieto, A; López Jimenez, J; López-Guillermo, A; Marín-Niebla, A; Martín García-Sancho, A; Medina Herrera, A; Muntañola, A; Nadeu, F; Rodríguez, S; Rotger, A; Setoain, X; Terol, MJ, 2022)
" The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily."2.90Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. ( Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L, 2019)
"We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators."2.87Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J, 2018)
"Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting."2.84Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. ( Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M, 2017)
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma."2.82Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. ( Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016)
" A total of 8/16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31."2.82Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. ( Choi, I; Fukuhara, N; Hatake, K; Ishikawa, T; Kinoshita, T; Kitano, T; Maruyama, D; Matsuno, Y; Nagai, H; Nishikawa, T; Nishikori, M; Shibayama, H; Takahara, S; Tobinai, K; Uchida, T, 2016)
" We developed a population pharmacokinetic (PK) model for ibrutinib in patients."2.80Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. ( Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015)
" Outcomes assessed included overall response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), and adverse events."2.61Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. ( Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J, 2019)
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas."2.61Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)
"Discussion One patient with chronic lymphocytic leukemia/small lymphocytic lymphoma and one patient with mantle cell lymphoma developed laboratory and clinical tumor lysis syndrome following initiation of ibrutinib therapy."2.58Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( Brown, JN; Hammond, JM; Titus-Rains, KS, 2018)
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs."2.53A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016)
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)."1.62Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. ( Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021)
"Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse."1.62Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. ( Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR, 2021)
"In severe enterovirus infections, we recommend subtyping for the development of efficient preventive and therapeutic strategies."1.56Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report. ( Cana, D; Hess, G; Higer, M; Podlech, J; Schadmand-Fischer, S; Schwarting, A; Teschner, D; Theobald, M; Wölfel, T, 2020)
"There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL)."1.51Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. ( Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2019)
"Invasive bacterial infections developed in 23 (53."1.48Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018)
" The additive and synergistic inhibition of this combination additionally supports a therapeutic strategy involving lower dosing of each drug to reduce potential side effects."1.48Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib. ( Curtis, A; Rajan, S; Rueter, J; Shopland, L; Zhang, R, 2018)
"Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy."1.46Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). ( Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M, 2017)
"Lercanidipine 10 mg daily was prescribed as an alternative antihypertensive drug."1.43Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. ( Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016)
"Among 31 patients who experienced disease progression following ibrutinib and underwent salvage therapy, the overall and complete response rates were 32% and 19%, respectively."1.42Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. ( Champlin, RE; Cheah, CY; Chihara, D; Fowler, NH; Hagemeister, FB; Romaguera, JE; Seymour, JF; Wang, ML, 2015)
" We investigated the efficacy of the histone deacetylase (HDAC) inhibitor vorinostat combined with one of several B-cell receptor (BCR) signaling inhibitors on MCL cell death and the underlying mechanisms, using MCL cell lines."1.42The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. ( Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T, 2015)
" We here compare bortezomib with carfilzomib and LU-102 in MM and MCL in vitro with regard to their effects on pIκB/NF-κB signaling and their cytotoxic activity in combination with ibrutinib."1.42The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. ( Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H, 2015)

Research

Studies (208)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's152 (73.08)24.3611
2020's56 (26.92)2.80

Authors

AuthorsStudies
Yuan, J1
Zhang, Q9
Wu, S2
Yan, S1
Zhao, R2
Sun, Y7
Tian, X2
Zhou, K1
Stewart, CM1
Michaud, L1
Whiting, K2
Nakajima, R1
Nichols, C2
De Frank, S1
Hamlin, PA2
Matasar, MJ1
Gerecitano, JF1
Drullinsky, P1
Hamilton, A1
Straus, D1
Horwitz, SM1
Kumar, A2
Moskowitz, CH1
Moskowitz, A1
Zelenetz, AD2
Rademaker, J1
Salles, G2
Seshan, V2
Schöder, H1
Younes, A2
Tsui, DWY1
Batlevi, CL1
Portell, CA3
Wages, NA2
Kahl, BS3
Budde, LE1
Chen, RW2
Cohen, JB2
Varhegyi, NE1
Petroni, GR2
Williams, ME4
Wang, M20
Ramchandren, R1
Chen, R1
Karlin, L1
Chong, G1
Jurczak, W11
Wu, KL1
Bishton, M2
Collins, GP1
Eliadis, P1
Peyrade, F1
Lee, Y1
Eckert, K1
Neuenburg, JK1
Tam, CS8
Jain, P4
Zhao, S3
Lee, HJ7
Hill, HA2
Ok, CY4
Kanagal-Shamanna, R4
Hagemeister, FB4
Fowler, N4
Fayad, L5
Yao, Y7
Liu, Y13
Moghrabi, OB1
Navsaria, L2
Feng, L2
Nogueras Gonzalez, GM2
Xu, G3
Thirumurthi, S3
Santos, D4
Iliescu, C1
Tang, G2
Medeiros, LJ4
Vega, F2
Avellaneda, M1
Badillo, M9
Flowers, CR2
Wang, L8
Wang, ML14
Giné, E2
de la Cruz, F1
Jiménez Ubieto, A1
López Jimenez, J1
Martín García-Sancho, A2
Terol, MJ1
González Barca, E1
Casanova, M1
de la Fuente, A1
Marín-Niebla, A2
Muntañola, A1
González-López, TJ1
Aymerich, M1
Setoain, X1
Cortés-Romera, M1
Rotger, A1
Rodríguez, S1
Medina Herrera, A1
García Sanz, R1
Nadeu, F2
Beà, S2
Campo, E2
López-Guillermo, A2
Nastoupil, L2
Westin, JR1
Samaniego, F3
Steiner, R1
Nair, R1
Iyer, SP1
Xuelin, H1
Wagner-Bartak, N2
Lin, P1
Wang, SA1
Jorgensen, J1
Yin, CC1
Li, S6
Patel, KP1
Mu, J2
Liu, M4
Wang, J11
Meng, J1
Zhang, R2
Jiang, Y2
Deng, Q2
Qualls, D1
Lam, HY1
Matasar, M1
Owens, C1
Espeleta, JA1
Qiu, A1
Subzwari, S1
Biggar, E1
Batlevi, C1
Siddiqi, T1
Coutre, S2
McKinney, M1
Barr, PM3
Rogers, K1
Mokatrin, A1
Valentino, R2
Szoke, A1
Deshpande, S4
Zhu, A1
Arango-Hisijara, I1
Osei-Bonsu, K1
O'Brien, S3
Zinzani, PL2
Martelli, M1
Ferrero, S2
Gentile, M2
Laurenti, L1
Romana Mauro, F1
Sportoletti, P1
Tedeschi, A2
Varettoni, M1
Visco, C1
Ye, H2
Huang, S6
Chen, Z6
Jiang, VC1
Sancho, JM1
Fernández, S1
Capote, FJ1
Cañigral, C1
Grande, C1
Donato, E1
Zeberio, I1
Puerta, JM1
Rivas, A1
Pérez-Ceballos, E1
Vale, A1
Salar, A1
González-Barca, E1
Teruel, A1
Pastoriza, C1
Conde-Royo, D1
Sánchez-García, J1
Barrenetxea, C1
Arranz, R1
Hernández-Rivas, JÁ3
Ramírez, MJ1
Jiménez, A2
Rubio-Azpeitia, E1
Jerkeman, M7
Trotman, J1
Belada, D1
Boccomini, C1
Flinn, IW1
Giri, P1
Goy, A6
Hermine, O1
Hong, X1
Kim, SJ3
Lewis, D2
Mishima, Y1
Özcan, M1
Perini, GF1
Pocock, C1
Song, Y3
Spurgeon, SE2
Storring, JM1
Walewski, J1
Zhu, J4
Qin, R1
Henninger, T2
Howes, A2
Le Gouill, S5
Dreyling, M12
Killock, D2
Freeman, CL1
Pararajalingam, P1
Jin, L1
Balasubramanian, S2
Jiang, A1
Xu, W3
Grau, M1
Zapukhlyak, M1
Boyle, M1
Hodkinson, B1
Schaffer, M1
Enny, C3
Sun, S3
Vermeulen, J6
Morin, RD2
Scott, DW1
Lenz, G3
Rai, S1
Tanizawa, Y1
Cai, Z1
Huang, YJ1
Taipale, K1
Tajimi, M1
Cliff, ERS1
Dickinson, M1
Ferhanoglu, B1
Birtas Atesoglu, E1
Ozbalak, M1
Eşkazan, AE1
Vorobyev, VI2
Gemdzhian, EG1
Fedorova, LV1
Mikhailova, NB1
Ilyasov, RK1
Kaleikina, LP1
Trubyakova, OS1
Kaplanov, KD1
Melnichenko, EV1
Martynova, EV1
Yakovleva, EP1
Li, OY1
Tarasenko, EV1
Chumakova, EP1
Bulieva, NB1
Nesterova, ES1
Margolin, OV1
Zherebtsova, VA1
Butaev, LS1
Ptushkin, VV2
Araujo-Ayala, F1
Dobaño-López, C1
Valero, JG1
Gava, F1
Faria, C1
Norlund, M1
Morin, R1
Bernes-Lasserre, P1
Serrat, N1
Playa-Albinyana, H1
Giménez, R1
Lagarde, JM1
Colomer, D1
Bezombes, C1
Pérez-Galán, P1
Nishiyama-Fujita, Y1
Nakazato, T1
Ito, C1
Ogura, S1
Mizuno, K1
Kamiya, T1
Aisa, Y1
Mori, T1
Wang, HY4
Liu, X7
Nunez-Cruz, S3
Jillab, M1
Melnikov, O1
Nath, K2
Glickson, J1
Wasik, MA4
Jeon, YW1
Yoon, S1
Min, GJ1
Park, SS1
Park, S3
Yoon, JH1
Lee, SE1
Cho, BS1
Eom, KS1
Kim, YJ1
Kim, HJ2
Lee, S1
Min, CK1
Lee, JW1
Cho, SG4
Kabadi, SM4
Near, A1
Wada, K1
Burudpakdee, C1
Liang, SH1
Chiu, CF1
Bai, LY1
Telford, C1
Abhyankar, S1
Song, J2
Signorovitch, J1
Zhao, J1
Yao, Z1
Nakamura, K1
Saburi, M1
Kondo, Y1
Soga, Y1
Itani, K1
Kohno, K1
Otsuka, M1
Nakayama, T1
Zhou, X2
Steinhardt, MJ1
Düll, J1
Krummenast, F1
Danhof, S1
Meckel, K1
Nickel, K1
Grathwohl, D1
Leicht, HB1
Rosenwald, A4
Einsele, H1
Rasche, L1
Kortüm, M1
Schmelz, JL1
Cramer, F1
Romaguera, JE4
Mosna, K1
Ladicka, M1
Drgona, L1
Vranovska, M1
Hojsikova, I1
Tomasova, R1
Danihel, L1
Kyselovic, J1
Babal, P1
Hanna, KS1
Campbell, M1
Husak, A1
Sturm, S1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Yan, Z1
Zhou, L1
Zhao, Y3
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Cheng, T1
Wang, B4
Wu, X3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J4
Gai, QY3
Wang, W3
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X5
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Jiang, H4
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X5
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L4
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH3
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S2
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X6
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y8
Gu, Z1
Dong, C2
Guo, G1
Li, L7
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X4
Xu, H2
Yang, G3
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J9
Du, S1
Zhou, H1
Cui, J1
Wu, W3
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H7
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J4
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Hu, T1
Wang, F2
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y6
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L2
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Luo, W1
Xiong, D1
Zhao, D2
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J4
Guo, W1
Liu, T3
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S4
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z3
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W2
Chen, W5
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L17
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C4
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G2
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL6
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS2
Jun, S1
Park, D1
Kim, HG1
Lee, JO2
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y2
Shen, Y1
Wang, Q3
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z3
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J3
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y4
Xue, H1
Zhang, W2
Ruan, Z1
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X2
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Terao, T1
Narita, K1
Tsushima, T1
Miura, D1
Takeuchi, M1
Matsue, K1
Tucker, D1
Morley, N2
MacLean, P1
Vandenberghe, E2
Booth, S1
Parisi, L2
Rule, S14
Dmitrieva, EA1
Nikitin, EA1
Ignatova, AA1
Poletaev, AV1
Seregina, EA1
Voronin, KA1
Polokhov, DM1
Maschan, AA1
Novichkova, GA1
Panteleev, MA1
Orlando, EJ1
Bogusz, AM1
Lacey, SF2
Strauser, HT1
Nejati, R1
Zhang, P1
Brooks, S1
Watt, C1
Melenhorst, JJ1
June, CH2
Schuster, SJ4
Scapinello, G1
Riva, M1
Branca, A1
Pizzi, M1
Bonaldi, L1
Martines, A1
Manni, S1
Visentin, A1
Trentin, L1
Semenzato, G1
Gurrieri, C1
Piazza, F1
Higer, M1
Cana, D1
Podlech, J1
Schadmand-Fischer, S1
Schwarting, A1
Teschner, D1
Theobald, M1
Wölfel, T1
Hess, G7
de Jong, J2
Mitselos, A1
Cordoba, R1
Panizo, C1
Wrobel, T1
Dlugosz-Danecka, M2
Sukbuntherng, J2
Ouellet, D1
Hellemans, P1
Davis, JE1
Handunnetti, SM1
Ludford-Menting, M1
Sharpe, C1
Blombery, P2
Anderson, MA4
Roberts, AW4
Seymour, JF7
Ritchie, DS1
Koldej, RM1
Hindilerden, F1
Yönal Hindilerden, İ1
Diz Küçükkaya, R1
Sharman, J2
Clark, J1
Andorsky, D1
Yasuda, H1
Tsukune, Y1
Inano, T1
Mori, Y1
Ota, Y1
Komatsu, N1
Okahashi, N1
Uchihara, M1
Hoshino, E1
Morschhauser, F1
Chiron, D4
Bouabdallah, K1
Cartron, G1
Casasnovas, O1
Bodet-Milin, C1
Ragot, S1
Bossard, C1
Nadal, N1
Herbaux, C1
Tessoulin, B2
Tchernonog, E1
Rossi, C1
McCulloch, R2
Gastinne, T1
Callanan, MB1
Danilov, AV2
Persky, DO2
Alsuliman, T1
Faict, S1
Malard, F1
Genthon, A1
Brissot, E1
Van de Wyngaert, Z1
Ikhlef, S1
Banet, A1
Lapusan, S1
Sestili, S1
Corre, E1
M'hammedi-Bouzina, F1
Schaeffer, L1
Legrand, O1
Dulery, R1
Mohty, M1
Marjanovic, Z1
Byfield, SD1
LE, L1
Olufade, T1
Maddocks, K5
Crosbie, N1
Eyre, TA1
Bolam, S1
Arasaretnam, A1
Creasey, T1
Goradia, H1
McMillan, A1
Dawi, S1
Harrison, S1
Miles, O1
Robinson, A1
Dutton, D1
Wilson, MR1
McKay, P1
Follows, G2
Phillips, N1
Patmore, R2
Lambert, J1
Osborne, W1
Johnston, R1
Kirkwood, AA1
Yi, JH1
Yoon, DH2
Suh, C2
Chang, MH1
Yang, DH1
Jo, JC1
Hyun, SY1
Eom, HS1
Kwon, JH1
Han, SH1
Lee, SS1
Kwak, JY1
Kim, SH1
Kim, DS1
Oh, SY1
Ryoo, HM1
Kim, WS1
Roulin, L1
Haioun, C1
Lemonnier, F1
Fuhr, V1
Vafadarnejad, E1
Dietrich, O1
Arampatzi, P1
Riedel, A1
Saliba, AE1
Rauert-Wunderlich, H3
Wang, MY1
Lwin, T3
Park, PM1
Gao, J1
Meads, MB2
Ren, Y2
Li, T1
Fahmi, NA1
Singh, S1
Sehgal, L1
Silva, AS1
Sotomayor, EM1
Shain, KH2
Cleveland, JL1
Qi, J2
Shah, BD1
Tao, J4
Kagiyama, Y1
Fujita, S1
Shima, Y1
Yamagata, K1
Katsumoto, T1
Nakagawa, M1
Honma, D1
Adachi, N1
Araki, K1
Kato, A1
Inaki, K1
Ono, Y1
Fukuhara, S1
Kobayashi, Y1
Tobinai, K3
Kitabayashi, I1
Deng, H1
Li, Q1
Pu, Y1
Qian, Z1
Leitinger, EJ1
Wright, RM1
Nelson, N1
Juneja, S1
Nowakowski, KE1
Abeykoon, JP1
Manske, M1
Stenson, MJ1
Timm, MM1
Hanson, CA1
Van Dyke, DL1
Dasari, S1
Witzig, TE1
Ghosh, N3
Emond, B1
Lafeuille, MH1
Côté-Sergent, A1
Lefebvre, P1
Huang, Q1
Nomie, K7
Bell, T3
Pham, L1
Kadri, S2
Segal, J1
Zhou, S3
Richard, S1
Sharma, S3
Oriabure, O2
Guo, H4
Tao, W1
Fang, B3
Ahmed, M5
Huang, SY1
Shao, Y1
Lam, L2
Yi, Q1
Srour, SA2
Romaguera, J4
Silva, A1
Shah, B4
Fu, K1
Bi, C1
Jacobson, T1
Silva, M1
Distler, A1
Darville, L1
Han, Y1
Rebatchouk, D1
Di Liberto, M3
Moscinski, LC1
Koomen, JM1
Dalton, WS1
Sotomayor, E1
Aw, A1
Brown, JR4
Murthy, V1
Weaving, S1
Paneesha, S1
Santucci Silva, R1
Rusconi, C3
Caballero, D3
Joao, C3
Witzens-Harig, M3
Bence-Bruckler, I3
Zhou, W2
Goldberg, JD3
Trambitas, C1
Traina, S2
Chiou, CF1
Diels, J1
Titus-Rains, KS1
Brown, JN1
Hammond, JM1
Conaway, MR1
Hagner, PR1
Chiu, H1
Ortiz, M1
Apollonio, B1
Couto, S1
Waldman, MF1
Flynt, E1
Ramsay, AG1
Trotter, M1
Gandhi, AK1
Chopra, R1
Thakurta, A1
Auer, R4
Kahl, B2
Cavazos, N1
Liu, B1
Clow, F3
Beaupre, D1
Wildgust, M1
Sudhakaran, S1
Bashoura, L1
Stewart, J2
Balachandran, DD1
Faiz, SA2
Law, YXT1
Lee, LS1
Vitagliano, O1
Trastulli, F1
Cacace, F1
Leone, S1
Memoli, M1
Scalia, G1
Notarangelo, M1
Mainolfi, CG1
De Renzo, A1
Pane, F1
Rudelius, M2
Rosenfeldt, MT1
Leich, E1
Solimando, AG1
Beilhack, A1
Ott, G2
Phillips, T2
Lossos, IS1
Hamadani, M2
Reeder, CB1
Barnett, E1
Bravo, MC1
Martin, P7
Lu, L1
Zhu, F1
Yang, DT1
Huang, W1
Safe, S1
Rui, L1
Hershkovitz-Rokah, O1
Pulver, D1
Shpilberg, O1
Li, G1
Moscinski, L1
Yu, M1
Ma, Z1
Jin, J2
Pan, J1
Li, F1
Eskelund, CW1
Hutchings, M1
Räty, R1
Wader, KF1
Laurell, A1
Toldbod, H1
Pedersen, LB1
Niemann, CU2
Dahl, C1
Kuitunen, H1
Geisler, CH1
Grønbæk, K1
Kolstad, A1
Restelli, V1
Lupi, M1
Vagni, M1
Chilà, R1
Bertoni, F3
Damia, G1
Carrassa, L1
Arora, PC1
Guan, J1
Huang, D1
Yakimchuk, K1
Okret, S1
Varughese, T1
Taur, Y1
Cohen, N1
Palomba, ML1
Seo, SK1
Hohl, TM1
Redelman-Sidi, G1
Smith, A1
Roman, E1
Appleton, S1
Howell, D1
Johnson, R1
Burton, C1
Trneny, M2
Offner, F2
Thieblemont, C5
Goldberg, J1
Curtis, A1
Rueter, J2
Rajan, S1
Shopland, L1
Pott, C2
Agarwal, R3
Handunnetti, S2
Hicks, RJ1
Burbury, K2
Turner, G1
Di Iulio, J1
Bressel, M1
Westerman, D1
Lade, S1
Dawson, SJ2
Dawson, MA3
Dreger, P1
Michallet, M1
Bosman, P1
Dietrich, S1
Sobh, M1
Boumendil, A1
Nagler, A1
Scheid, C1
Cornelissen, J1
Niederwieser, D1
Müller, L1
Scortechini, I1
Schoemans, H1
Andersen, NS1
Finke, J1
Russo, D1
Ljungman, P1
Passweg, J1
van Gelder, M1
Durakovic, N1
Labussiere-Wallet, H1
Berg, T1
Wulf, G1
Bethge, W1
Bunjes, D1
Stilgenbauer, S3
Canepari, ME1
Schaap, M1
Fox, CP1
Kröger, N1
Montoto, S1
Schetelig, J1
Awan, FT1
Tarapore, R1
Prabhu, V1
Allen, J1
Schalop, L1
Zloza, A1
Sadimin, ET1
Schenkel, J1
Hagemeister, F3
Westin, J2
Till, BG1
Shaikh, H1
Khattab, A1
Faisal, MS1
Chilkulwar, A1
Albrethsen, M1
Sadashiv, S1
Fazal, S1
Hillmen, P1
Fraser, G1
Burger, JA2
Dilhuydy, MS1
Moreno, C1
Cramer, P1
Liu, E1
Chang, S2
Styles, L1
James, DF1
Patel, K1
Graef, T1
Lee, J2
Zhang, LL1
Sukhanova, M2
Venkataraman, G1
Alikhan, M1
Lu, P4
Guo, A2
Galanina, N1
Andrade, J1
Ghorab, A1
Zeng, D2
Gong, T2
Neelapu, S1
Champlin, R2
Tappenden, P1
Simpson, E1
Hamilton, J1
Pollard, D1
Clowes, M1
Kaltenthaler, E1
Meiklejohn, D1
Yao, J1
Li, CJ1
Lorence, E3
Jiang, C1
Nomie, KJ1
da Cunha-Bang, C1
Dolgin, E1
Qi, K1
Sales De Gauzy, T1
Oberic, L1
Fournié, P1
Soler, V1
Chan, YC1
Hunter, T1
Vassiliadis, D1
Teh, CE1
Thijssen, R1
Yeh, P1
Wong, SQ1
Ftouni, S1
Lam, EYN1
Gilan, O1
Bell, CC1
Knezevic, K1
Rayeroux, K1
Zordan, A1
Huang, DCS1
Wall, M1
Gray, DHD1
Ming, M1
Xie, B1
Shacham, S1
Landesman, Y1
Maltsev, N1
Dobrovolsky, D1
Wang, ES1
Morrow, S1
Leahy, C1
Faust, T1
Nowak, RP1
Donovan, KA1
Fischer, ES1
Treon, SP1
Weinstock, DM2
Gray, NS1
Davids, MS1
Kim, HT1
Nicotra, A1
Savell, A1
Francoeur, K1
Hellman, JM1
Bazemore, J1
Miskin, HP1
Sportelli, P1
Stampleman, L1
Maegawa, R1
Boruchov, AM1
Arnason, JE1
Jacobson, CA1
Jacobsen, ED2
Fisher, DC1
Robak, T2
Mori, S1
Patel, RD1
Ahmad, S1
Varela, J1
Smith, T1
Altoos, R1
Shen, Q1
Goldstein, SC1
Morabito, F1
Skafi, M1
Recchia, AG1
Kashkeesh, A1
Hindiyeh, M1
Sabatleen, A1
Morabito, L1
Alijanazreh, H1
Hamamreh, Y1
Uchida, T2
Fukuhara, N2
Nishikawa, T2
Długosz-Danecka, M1
Tarantelli, C1
Curti, E1
Gaudio, E1
Spriano, F1
Priebe, V1
Cascione, L1
Arribas, AJ1
Zucca, E2
Rossi, D1
Stathis, A1
Bartlett, NL1
Blum, KA4
Ruan, J2
Ridling, L1
Dittus, C1
Inghirami, G1
DiLiberto, M2
Chen-Kiang, S4
Leonard, JP3
Jung, D1
Caldeira, D1
Alves, D1
Costa, J1
Ferreira, JJ1
Pinto, FJ1
Styskel, BA1
Lopez-Mattei, J1
Jimenez, CA1
D'Agaro, T1
Zucchetto, A1
Vit, F1
Bittolo, T1
Tissino, E1
Rossi, FM1
Degan, M1
Zaja, F1
Bulian, P1
Bo, MD1
Ladetto, M1
Zamò, A1
Gattei, V1
Bomben, R1
Ding, N1
Rao, Y1
Lee, SC1
Shestov, AA1
Roman, JC1
Pickup, S1
Hofbauer, S1
Mesaros, C1
Nelson, DS1
Blair, IA1
Glickson, JD1
Papin, A1
Bellanger, C1
Moreau, A1
Le Bris, Y1
Maisonneuve, H1
Moreau, P2
Touzeau, C2
Amiot, M2
Pellat-Deceunynck, C2
Schamroth Pravda, M1
Schamroth Pravda, N1
Lishner, M1
Di Francesco, ME1
Feng, N1
Haun, R1
Lan, R1
Mackintosh, SG1
Mao, X1
Song, X2
Pham, LV2
Lorenzi, PL1
Marszalek, J1
Heffernan, T1
Draetta, G1
Jones, P1
Futreal, A1
Choi, YJ1
Kim, DH1
Choi, CM1
Lee, JC1
Hong, JY1
Rho, JK1
Best, S1
Bruss, N1
Kittai, A1
Berger, A1
Flinsenberg, TWH1
Tromedjo, CC1
Hu, N1
Thia, KYT1
Noori, T1
Aw Yeang, HX1
Tantalo, DG1
Ritchie, D1
Koldej, R1
Neeson, PJ1
Trapani, JA1
Voskoboinik, I1
Bond, DA1
Alinari, L2
Fradley, MG1
Gliksman, M1
Emole, J1
Viganego, F1
Rhea, I1
Welter-Frost, A1
Armanious, M1
Lee, DH1
Walko, C1
Chavez, JC1
McLeod, H1
Pinilla-Ibarz, J1
Schabath, MB1
Buggy, JJ3
Newberry, KJ1
Advani, RH1
Barrientos, JC1
Chmielowska, E2
Radford, J1
Jedrzejczak, WW1
Johnson, P1
Newberry, K1
Ou, Z1
Cheng, N1
McGreivy, J3
Chang, BY2
Beaupre, DM2
Kunkel, LA1
Francesco, M1
De Rooij, MF2
Magadala, P1
Steggerda, SM1
Huang, MM1
Kuil, A2
Herman, SE2
Pals, ST2
Wilson, W1
Wiestner, A3
Spaargaren, M2
Elias, L1
Cinar, M1
Hamedani, F1
Mo, Z1
Cinar, B1
Amin, HM2
Alkan, S1
Sharma, SP1
Rahal, R1
Frick, M1
Romero, R1
Korn, JM1
Kridel, R1
Chan, FC1
Meissner, B1
Bhang, HE1
Ruddy, D1
Kauffmann, A1
Farsidjani, A1
Derti, A1
Rakiec, D1
Naylor, T1
Pfister, E1
Kovats, S1
Kim, S1
Dietze, K1
Dörken, B1
Steidl, C1
Tzankov, A1
Hummel, M1
Monahan, J1
Morrissey, MP1
Fritsch, C1
Sellers, WR1
Cooke, VG1
Gascoyne, RD1
Stegmeier, F1
Cameron, F1
Sanford, M1
Guha, M1
McDermott, J1
Jimeno, A1
Ma, J1
Cheng, S1
Zong, H1
Coleman, M1
Small, S1
Blecua, P1
Mathew, S1
Vijay, P1
Eng, K2
Ali, S1
Johnson, A1
Chang, B1
Ely, S1
Elemento, O2
Mason, CE1
Kamel, S1
Horton, L1
Ysebaert, L1
Levade, M1
Tan, S1
Cole-Sinclair, M1
Reynolds, J1
Filshie, R1
Schischka, S1
Khot, A1
Sandhu, S1
Keating, MJ2
Nandurkar, H1
Shah, N1
Hutchinson, C1
Bodo, J2
Sun, D1
Durkin, L2
Lin, J1
Smith, MR3
Hsi, ED2
Herrera, AF1
Marostica, E1
Loury, D1
de Trixhe, XW1
Vermeulen, A1
De Nicolao, G1
Byrd, JC1
Advani, R2
Poggesi, I1
Bernard, S2
Danglade, D1
Gardano, L1
Laguillier, C1
Lazarian, G1
Roger, C1
Marzec, J1
Gribben, J1
Cymbalista, F1
Varin-Blank, N1
Ledoux, D1
Baran-Marszak, F1
Sinha, G1
Rattu, MA1
Kim, SS1
McMullen, JR1
Boey, EJ1
Ooi, JY1
Mancebo, SE1
Smith, JR1
Intlekofer, AM1
Myskowski, PL1
Furtado, M1
Munneke, B1
Cheah, CY2
Chihara, D2
Fowler, NH1
Champlin, RE1
Dousset, C1
Brosseau, C1
Maïga, S1
Kim, ES1
Dhillon, S1
Herishanu, Y1
Katz, BZ1
Hagiwara, K2
Kunishima, S1
Iida, H2
Miyata, Y1
Naoe, T1
Nagai, H3
Kater, AP1
Kersten, MJ1
Shetty, S1
Kraus, J1
Kraus, M1
Liu, N1
Besse, L1
Bader, J1
Geurink, PP1
de Bruin, G1
Kisselev, AF1
Overkleeft, H1
Driessen, C1
Berglöf, A1
Hamasy, A1
Meinke, S1
Palma, M1
Krstic, A1
Månsson, R1
Kimby, E2
Österborg, A1
Smith, CI1
Goldwirt, L1
Amorim, S1
Brice, P1
Brière, J1
de Kerviler, E1
Mourah, S1
Sauvageon, H1
Sun, B1
Fiskus, W1
Rajapakshe, K1
Coarfa, C1
Devaraj, SG1
Saenz, DT1
Krieger, S1
Bradner, JE1
Bhalla, KN1
de Claro, RA1
McGinn, KM1
Verdun, N1
Lee, SL1
Chiu, HJ1
Saber, H1
Brower, ME1
Chang, CJ1
Pfuma, E1
Habtemariam, B1
Bullock, J1
Nie, L1
Chen, XH1
Lu, DR1
Al-Hakim, A1
Kane, RC1
Kaminskas, E1
Justice, R1
Farrell, AT1
Pazdur, R1
Gayko, U1
Fung, M1
Faust, E1
Price, S1
James, D1
Doyle, M1
Bari, S1
Zhuang, SH1
Smolewski, P1
Witkowska, M1
Tokunaga, T1
Lee, H1
Chuang, H1
Turturro, F1
Oki, Y1
DeLa Rosa, M1
Addison, A1
Young, KH1
Silva, RS1
Bothos, J1
Bandyopadhyay, N1
Rizo, A1
Tucker, DL2
Rule, SA2
Wagner-Johnston, N1
Iberri, D1
Spurgeon, S1
Kozin, E1
Noto, K1
Bloehdorn, J1
Portell, C1
Furman, RR1
Lambert Kuhn, E1
Levêque, D1
Lioure, B1
Gourieux, B1
Bilbault, P1
Ruella, M2
Kenderian, SS1
Shestova, O1
Fraietta, JA1
Qayyum, S1
Maus, MV1
Klichinsky, M1
Kawalekar, OU1
Milone, M1
Mato, A1
Kalos, M1
Gill, S1
Dougé, A1
Ravinet, A1
Bay, JO1
Tournilhac, O1
Guièze, R1
Lemal, R1
Kaur, V1
Swami, A1
Mouhayar, E1
Kim, P1
Saba, NS1
Liu, D1
Underbayev, C1
Behrend, D1
Weniger, MA1
Skarzynski, M1
Gyamfi, J1
Fontan, L1
Melnick, A1
Grant, C1
Roschewski, M1
Navarro, A1
Pittaluga, S1
Dunleavy, K1
Wilson, WH1
Naylor, G1
Kruger, A1
Hamilton, MS1
Wu, C1
de Miranda, NF1
Wasik, AM1
Mansouri, L1
Galazka, K1
Machaczka, M1
Peng, R1
Rosenquist, R1
Sander, B1
Pan-Hammarström, Q1
Maruyama, D1
Kitano, T1
Ishikawa, T1
Shibayama, H1
Choi, I1
Hatake, K1
Nishikori, M1
Kinoshita, T1
Matsuno, Y1
Takahara, S1
Mohanty, A1
Sandoval, N1
Das, M1
Pillai, R1
Marcucci, G1
Weisenburger, DD1
Rosen, ST1
Ngo, VN1
Jacobson, C1
Kopp, N1
Layer, JV1
Redd, RA1
Tschuri, S1
Haebe, S1
van Bodegom, D1
Bird, L1
Christie, AL1
Christodoulou, A1
Saur, A1
Tivey, T1
Zapf, S1
Bararia, D1
Zimber-Strobl, U1
Rodig, SJ1
Weigert, O1
Soubeyran, P1
González-Bonet, LG1
García-Boyero, R1
Gaona-Morales, J1
Epperla, N1
Cashen, AF1
Ahn, KW1
Oak, E1
Kanate, AS1
Calzada, O1
Farmer, L1
Tallarico, M1
Nabhan, C1
Costa, LJ1
Kenkre, VP1
Hari, PN1
Fenske, TS1
Compagno, M1
Pighi, C1
Cheong, TC1
Meng, FL1
Poggio, T1
Yeap, LS1
Karaca, E1
Blasco, RB1
Langellotto, F1
Ambrogio, C1
Voena, C1
Kasar, SN1
Wu, CJ1
Gostissa, M1
Alt, FW1
Chiarle, R1
Diamantopoulos, PT1
Psichogiou, M1
Pantazatou, A1
Zervakis, K1
Rougala, N1
Giannakopoulou, N1
Daikos, G1
Viniou, NA1
Hallek, M1
Staudt, L1
Christian, B1
Baiocchi, RA1
Dasmahapatra, G1
Patel, H1
Dent, P1
Fisher, RI1
Friedberg, J1
Grant, S1

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma[NCT02756247]Phase 137 participants (Actual)Interventional2016-05-09Completed
Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma[NCT02419560]Phase 137 participants (Actual)Interventional2015-04-30Completed
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma[NCT03112174]Phase 3352 participants (Actual)Interventional2017-06-29Active, not recruiting
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620]Phase 2131 participants (Anticipated)Interventional2015-06-03Active, not recruiting
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL[NCT01880567]Phase 2113 participants (Actual)Interventional2013-07-15Active, not recruiting
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma[NCT02682641]Phase 250 participants (Anticipated)Interventional2016-05-18Active, not recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma[NCT01776840]Phase 3523 participants (Actual)Interventional2013-05-16Active, not recruiting
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207]Phase 125 participants (Actual)Interventional2017-10-20Completed
A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)[NCT02471391]Phase 237 participants (Actual)Interventional2015-07-22Active, not recruiting
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients[NCT02558816]Phase 1/Phase 248 participants (Actual)Interventional2015-10-14Active, not recruiting
A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma[NCT00875667]Phase 2254 participants (Actual)Interventional2009-04-30Completed
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.[NCT02341781]30 participants (Actual)Observational2015-04-30Completed
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma[NCT02460276]Phase 250 participants (Actual)Interventional2015-04-30Completed
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies[NCT02268851]Phase 145 participants (Actual)Interventional2014-11-30Active, not recruiting
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma[NCT03478514]Phase 239 participants (Actual)Interventional2018-09-11Active, not recruiting
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma[NCT02159755]Phase 128 participants (Actual)Interventional2014-05-20Active, not recruiting
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497]Phase 110 participants (Actual)Interventional2017-09-05Active, not recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma[NCT01236391]Phase 2115 participants (Actual)Interventional2011-02-28Completed
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236]Phase 127 participants (Actual)Interventional2015-06-18Active, not recruiting
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725]Phase 114 participants (Actual)Interventional2019-08-29Active, not recruiting
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics[NCT00114738]Phase 253 participants (Actual)Interventional2005-06-15Completed
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392]Phase 324 participants (Anticipated)Interventional2021-09-14Recruiting
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654]Phase 166 participants (Actual)Interventional2009-02-28Completed
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents[NCT03816683]229 participants (Actual)Observational2019-04-01Active, not recruiting
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy[NCT01646021]Phase 3280 participants (Actual)Interventional2012-12-10Completed
Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients:a Single Arm, Open-labelled, Phase 2 Study[NCT03016988]Phase 250 participants (Anticipated)Interventional2017-01-31Not yet recruiting
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955]Phase 28 participants (Actual)Interventional2018-06-12Completed
A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02169180]Phase 216 participants (Actual)Interventional2014-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State

Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Interventionnanogram*hour per milliliter (ng*h/mL) (Mean)
Ibrutinib + BR (Treatment B)425

Complete Response Rate

Complete response (CR) rate is defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01776840)
Timeframe: Up to 97 months

Interventionpercentage of participants (Number)
Ibrutinib + BR (Treatment B)65.5
Placebo + BR (Treatment A)57.6

Duration of Complete Response (DoCR)

Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first, for participants who achieved CR. (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)NA
Placebo + BR (Treatment A)78.1

Duration of Response (DoR)

Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death. (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)81
Placebo + BR (Treatment A)63.5

Maximum Observed Plasma Concentration of Ibrutinib

Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Interventionng/mL (Mean)
Ibrutinib + BR (Treatment B)74.5

Minimal Residual Disease (MRD)-Negative Response Rate

Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, <5 mantle cell lymphoma [MCL] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample. (NCT01776840)
Timeframe: Up to 97 months

Interventionpercentage of participants (Number)
Ibrutinib + BR (Treatment B)62.1
Placebo + BR (Treatment A)56.5

Minimum Observed Plasma Concentration of Ibrutinib

Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Interventionnanograms per milliliter (ng/mL) (Mean)
Ibrutinib + BR (Treatment B)3.90

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. Treatment-emergent adverse events are defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier. (NCT01776840)
Timeframe: Up to 97 months

InterventionParticipants (Count of Participants)
Ibrutinib + BR (Treatment B)259
Placebo + BR (Treatment A)257

Oral Plasma Clearance (CL/F) of Ibrutinib

CL/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling). (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Interventionliter per hour (L/h) (Mean)
Ibrutinib + BR (Treatment B)1123

Oral Volume of Distribution at Steady State of Ibrutinib

Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)

Interventionliter (Mean)
Ibrutinib + BR (Treatment B)7286

Overall Survival

Overall survival is defined as the time from the date of randomization to the date of the participant's death. (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)NA
Placebo + BR (Treatment A)NA

Percentage of Participants With Overall Response

Percentage of participants with overall response that is participants who achieved CR or PR was reported. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. (NCT01776840)
Timeframe: Up to 97 months

Interventionpercentage of participants (Number)
Ibrutinib + BR (Treatment B)89.7
Placebo + BR (Treatment A)88.5

Progression-free Survival (PFS)

Progression-free survival (PFS) is defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever is first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD is defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters [cm] in any axis, 50% increase in sum of product of diameters [SPD] of greater than [>] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis). (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)80.6
Placebo + BR (Treatment A)52.9

Time to Response

Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response. (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)2.79
Placebo + BR (Treatment A)2.79

Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire

"Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being too ill, whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life." (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)17.4
Placebo + BR (Treatment A)22.2

Time-to-Next Treatment

Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment. (NCT01776840)
Timeframe: Up to 97 months

Interventionmonths (Median)
Ibrutinib + BR (Treatment B)NA
Placebo + BR (Treatment A)92.0

Kaplan Meier Estimate for Duration of Response (DOR) According to the IRC Central Review

Duration of response was defined as the time from when the first response of CR, CRu, or PR was first achieved until documented tumor progression, or until the participant died from any cause, whichever occurred first. Participants who did not progress or die at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median study duration was 70.7 weeks for the lenalidomide arm and 69.3 weeks for the investigators choice arm

InterventionWeeks (Median)
Lenalidomide69.6
Investigators Choice45.1

Kaplan Meier Estimate for Duration of Response as Assessed by the Investigator at the Final Analysis

Duration of response was defined as the time from when the first response of CR, CRu, or PR was first achieved until documented tumor progression, or until the participant died from any cause, whichever occurred first. Participants who did not progress or die at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median study duration was 103.9 weeks for lenalidomide and 87.0 weeks for the investigator choice arm

InterventionWeeks (Median)
Lenalidomide70.1
Investigators Choice91.7

Kaplan Meier Estimate for Overall Survival (OS) According to the IRC Central Review

Overall survival was defined as the time from randomization until death from any cause. Participants alive or lost to follow-up at the time of analysis were censored at the last date they were known to be alive. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; overall median follow-up was 93.9 weeks

Interventionweeks (Median)
Lenalidomide121.0
Investigators Choice91.7

Kaplan Meier Estimate for Overall Survival as Assessed by the Investigator at the Final Analysis

Overall survival was defined as the time from randomization until death from any cause. Participants alive or lost to follow-up at the time of analysis were censored at the last date they were known to be alive. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to the study discontinuation date of 09 October 2018; overall median follow-up time was 285 weeks

Interventionweeks (Median)
Lenalidomide120.6
Investigators Choice91.7

Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review

PFS was defined as time of randomization to the first observation of disease progression or death due to any cause, whichever was first. If a participant had not progressed or died, PFS was censored at the time of last assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to data cut off date of 07 March 2014; overall median follow-up time was 93.9 weeks

Interventionweeks (Median)
Lenalidomide37.6
Investigators Choice22.7

Kaplan Meier Estimate for Progression Free Survival by Investigator's Assessment at the Final Analysis

Kaplan Meier estimates of PFS were defined as the time from randomization to the first observation of disease progression or death due to any cause, whichever was first. If a participant had not progressed or died, PFS was censored at the time of last completed assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to study discontinuation of 09 October 2018; overall median follow-up time was 285 weeks

Interventionweeks (Median)
Lenalidomide37.3
Investigators Choice23.6

Kaplan Meier Estimate of Time to First Response (TTFR) According to the IRC Central Review

Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants. ). Participants with progression at the time of analysis were censored at the first assessment date that the participant was known to have progressed. Participants with SD at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From randomization of study drug to time of first documented PR or better response; up to data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm

InterventionWeeks (Median)
Lenalidomide18.7
Investigators ChoiceNA

Kaplan Meier Estimate of Time to First Response as Assessed by the Investigator at the Final Analysis

Time to first response was defined as the time from first dose of study drug to the date of the first response (having at least a PR). Participants with progression at the time of analysis were censored at the first assessment date that the participant was known to have progressed. Participants with SD at the time of analysis were censored at the last assessment date that the subject was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm

InterventionWeeks (Median)
Lenalidomide23.9
Investigators Choice40.0

Kaplan Meier Estimate of Time to Progression According to the IRC Central Review

Time to progression (TTP) was defined as the time from randomization until objective tumor progression. Time to progression did not include deaths. Participants without progression at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new anti-lymphoma treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median study duration was 70.7 weeks for the lenalidomide arm and 69.3 weeks for the investigators choice arm

InterventionWeeks (Median)
Lenalidomide39.3
Investigators Choice24.7

Kaplan Meier Estimate of Time to Progression as Assessed by the Investigator at the Final Analysis

Time to progression (TTP) was defined as the time from randomization until objective tumor progression. Time to progression did not include deaths. Participants without progression at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new anti-lymphoma treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median study duration was 103.9 weeks for lenalidomide and 87.0 weeks for the investigator choice arm

InterventionWeeks (Median)
Lenalidomide39.3
Investigators Choice24.7

Kaplan Meier Estimate of Time to Treatment Failure (TTF) as Assessed by the Investigator

Time to treatment failure was defined as the time from the first dose of study drug to discontinuation of treatment for any reason, including disease progression assessed by the investigator, treatment toxicity, or death. Participants who were on-treatment or completed the treatment according to the protocol were censored at the last date of drug intake. (NCT00875667)
Timeframe: From the date of the first treatment to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm

Interventionweeks (Median)
Lenalidomide24.4
Investigators Choice17.9

Kaplan Meier Estimate of Time to Treatment Failure as Assessed by the Investigator at the Final Analysis

Time to treatment failure was defined as the time from the first dose of study drug to discontinuation of treatment for any reason, including disease progression assessed by the investigator, treatment toxicity, or death. Participants who were on-treatment or completed the treatment according to the protocol were censored at the last date of drug intake. (NCT00875667)
Timeframe: From date of first dose of treatment to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm

Interventionweeks (Median)
Lenalidomide24.4
Investigators Choice17.9

Maximum Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Domain to Treatment Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-4.8
Investigators Choice-4.1

Maximum Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide3.2
Investigators Choice2.9

Maximum Change From Baseline in the EORTC QLQ-C30 Constipation Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-0.3
Investigators Choice-3.5

Maximum Change From Baseline in the EORTC QLQ-C30 Diarhoea Domain to Treatment Discontinuation Visit

"The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).~The EORTC QLQ-C30 Diarhoea Scale was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement." (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and time of discontinuation from treatment visit.Up to final data cut-0ff date of 07 March 2014

Interventionunits on a scale (Least Squares Mean)
Lenalidomide-7.2
Investigators Choice-5.8

Maximum Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Domain to Treatment Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-7.3
Investigators Choice-5.8

Maximum Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide6.9
Investigators Choice3.7

Maximum Change From Baseline in the EORTC QLQ-C30 Fatigue Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-4.9
Investigators Choice-2.9

Maximum Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Problems Domain Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-10.9
Investigators Choice-2.3

Maximum Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status / QoL Domain to Treatment Scale was scored between 0 and 100, with a higher score representing a higher quality of life. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide4.6
Investigators Choice5.6

Maximum Change From Baseline in the EORTC QLQ-C30 Insomnia Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-12.8
Investigators Choice-7.6

Maximum Change From Baseline in the EORTC QLQ-C30 Nausea and Vomiting Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea and Vomiting Scale was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide-2.3
Investigators Choice-0.6

Maximum Change From Baseline in the EORTC QLQ-C30 Pain Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and time of discontinuation from treatment visit.Up to final data cut-0ff date of 07 March 2014

Interventionunits on a scale (Mean)
Lenalidomide-5.8
Investigators Choice-3.5

Maximum Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide3.4
Investigators Choice-1.8

Maximum Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide3.1
Investigators Choice5.0

Maximum Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

Interventionunits on a scale (Mean)
Lenalidomide5.1
Investigators Choice3.8

Percentage of Participants Who Achieved an Overall Response According to the IRC Central Review

Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response (CR), Complete Response unconfirmed (CRu) or Partial Response (PR). Participants who discontinued before any response had been observed or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999; CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm

InterventionPercentage of Participants (Number)
Lenalidomide40.0
Investigators Choice10.7

Percentage of Participants Who Achieved an Overall Response as Assessed by the Investigator at the Final Analysis

Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999; CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm

InterventionPercentage of Participants (Number)
Lenalidomide45.9
Investigators Choice22.6

Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease According to the IRC Central Review

Tumor control rate was defined as the percentage of participants with a complete response (CR), unconfirmed complete response (CRu), partial response (PR) and stable disease (SD). Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. Stable disease (SD) is defined as less than a PR (see above) but is not progressive disease or relapsed disease. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm

InterventionPercentage of Participants (Number)
Lenalidomide69.4
Investigators Choice63.1

Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease at the Final Analysis

Tumor control rate was defined as the percentage of participants with a complete response (CR), unconfirmed complete response (CRu), partial response (PR) and stable disease (SD). Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. Stable disease (SD) is defined as less than a PR (see above) but is not progressive disease or relapsed disease. (NCT00875667)
Timeframe: From date of randomization to the discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm

InterventionPercentage of participants (Number)
Lenalidomide70.0
Investigators Choice65.5

Mean Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice16.2-0.85.1-12.5-11.15.4
Lenalidomide18.12.51.9-2.3-4.34.8

Mean Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice83.6-2.31.34.25.6-2.3
Lenalidomide84.60.0-1.9-3.2-2.5-5.1

Mean Change From Baseline in the EORTC QLQ-C30 Constipation

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Domain was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice8.6-0.81.30.00.00.8
Lenalidomide12.56.34.23.5-0.710.2

Mean Change From Baseline in the EORTC QLQ-C30 Diarhoea

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarhoea Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice12.6-3.11.3-4.20.00.0
Lenalidomide15.7-3.5-4.22.4-2.11.6

Mean Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Domain was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice21.2-0.80.04.25.60.8
Lenalidomide26.5-1.6-1.4-2.91.46.0

Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice78.51.31.3-3.11.4-1.5
Lenalidomide73.73.43.68.14.5-1.3

Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice39.22.13.4-6.9-7.42.6
Lenalidomide40.20.1-3.2-1.0-3.95.2

Mean Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Problems Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice10.8-0.8-3.8-4.2-5.61.6
Lenalidomide19.5-7.0-7.0-2.9-9.2-4.3

Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status / QoL Domain was scored between 0 and 100, with a higher score representing a higher quality of life. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice58.42.33.27.38.3-1.0
Lenalidomide59.0-3.4-0.71.04.3-5.8

Mean Change From Baseline in the EORTC QLQ-C30 Insomnia Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice25.7-4.7-6.4-16.7-16.70.8
Lenalidomide29.4-7.6-5.2-1.8-7.1-3.2

Mean Change From Baseline in the EORTC QLQ-C30 Nausea / Vomiting Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea and Vomiting Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice3.80.45.82.12.86.6
Lenalidomide4.92.52.65.3-0.70.5

Mean Change From Baseline in the EORTC QLQ-C30 Pain Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineCycle 3 Day 1Cycle 5 Day 1Cycle 7 Day 1Cycle 9 Day 1Treatment Discontinuation
Investigators Choice13.7-1.2-2.60.0-2.83.5
Lenalidomide22.6-2.2-0.23.2-3.24.6

Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice78.9-3.7-2.14.211.1-5.1
Lenalidomide71.8-0.51.62.42.8-5.6

Mean Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice73.93.5-6.40.013.9-4.3
Lenalidomide71.5-4.81.40.31.8-9.1

Mean Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain

The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.

,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Cycle 3 Day 1Change from Baseline to Cycle 5 Day 1Change from Baseline to Cycle 7 Day 1Change from Baseline to Cycle 9 Day 1Change from Baseline to Treatment Discontinuation
Investigators Choice78.4-1.2-4.52.10.0-2.7
Lenalidomide74.9-1.01.6-1.54.3-5.1

Number of Participants With Treatment Emergent Adverse Events

Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A Treatment Emergent Adverse event (TEAE) is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. (NCT00875667)
Timeframe: From the date of the first dose of study drug to 28 days after the last dose, up to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigators choice arm

,
InterventionParticipants (Count of Participants)
Any TEAEAny TEAE Grade 3 AEAny TEAE Grade 4 AEAny TEAE Grade 5 AEAny TEAE Related to the IPAny Grade 3 AE Related to IPAny Grade 4 AE Related to IPAny Grade 5 AE Related to IPAny Serious Adverse Event (SAE)Any SAE Related to IPAny TEAE Leading to Stopping of IPAny Treatment Related AE Leading to Stopping IPTEAE Leading to Dose Reduction/InterruptionRelated AE Leading to Dose Reduct/InterruptionTEAE Leading to Dose ReductionRelated AE Leading to Dose ReductionTEAE Leading to Dose InterruptionRelated AE Leading to Dose Interruption
Investigators Choice694929251361902212147332913102825
Lenalidomide159126561514110646075383118114103726911098

Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I

To assess the safety of TGR1202 in combination with ibrutinib relapsed or refractory CLL or MCL. DLT is based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. DLT refers to toxicities experienced at any time during the study treatment, defined as Grade 4 anemia; Grade 4 neutropenia lasting >7 days (while receiving growth factor support); Grade 4 thrombocytopenia lasting > 7 days; Grade ≥3 febrile neutropenia; and Grade ≥3 thrombocytopenia with Grade >2 hemorrhage;Grade ≥ 3 non-hematologic toxicity unresponsive to standard supportive care measure with the exception of asymptomatic Grade ≥3 lab abnormalities that resolve to ≤ Grade 1 or baseline within 7 days;treatment delay of ≥14 days due to unresolved toxicity; and non-hematologic toxicity of Grade 2 (at any time during treatment) that, in the judgment of the Investigators, Study Chair, and the Medical Monitor, is dose-limiting. (NCT02268851)
Timeframe: Participants were assessed every week or more often as needed during Cycle 1 or more often for up to 28 days to assess Dose-limiting toxicities (DLTs) during Phase I

InterventionParticipants (Count of Participants)
CLL: Phase I Cohort 10
MCL: Phase 1 Cohort 10
CLL: Phase I Cohort 20
MCL: Phase I Cohort 20
CLL Phase I/IICohort 3 (RPD2)0
MCL Phase I/II Cohort 3 (RPD2)0

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score

Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change. (NCT01236391)
Timeframe: From Baseline to Cycle 5 (Week 20)

Interventionscores on a scale (Mean)
EORTC QLQ-C300.6

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE (NCT01236391)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

Interventionparticipants (Number)
PCI-32765111

PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h) (NCT01236391)
Timeframe: Performed During the First Month of Receiving PCI-32765

InterventionAUC0-24h (ng*h/mL) (Mean)
PCI-32765 - Day 8953
PCI-45227 (Metabolite)- Day 81263

Percentage of Participants Achieving Response

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a >/= 50% decrease in the sum of the product of diameters of the target lesions, and >/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions. (NCT01236391)
Timeframe: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months

Interventionpercentage of participants with response (Number)
PCI-3276567.6

Count of Participants With Serious and Non-Serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00114738)
Timeframe: Date treatment consent signed to date off study, approximately 143 months and 7 days

InterventionParticipants (Count of Participants)
EPOCH-R+Bortezomib53

Median Overall Survival (OS)

Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years

InterventionMonths (Median)
EPOCH-R+Bortezomib80.4

Overall Progression Free Survival

Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 9.9 years

InterventionMonths (Median)
EPOCH-R+Bortezomib29.3

Overall Survival

Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years

InterventionMonths (Median)
Bortezomib Maintenance78.6
Observation87.5
Not Randomized31.6

Progression Free Survival (PFS)

Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes.The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 5 years

InterventionMonths (Median)
Bortezomib Maintenance27.2
Observation33.5
Not Randomized7.8

Clinical Response

Clinical response is assessed by the response criteria for lymphomas and is defined as a fraction of patients who have a complete response (CR) or a complete response (CR) + partial response (PR). A complete response is disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g. lactate dehydrogenase) definitely assignable to the lymphoma. Partial response is ≥50% decreased in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen, ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 22 weeks after initiation of therapy

InterventionPercentage of patients (Number)
Overall Response (CR+PR)Complete ResponseStable DiseaseProgressive DiseaseNot Evaluable
EPOCH-R+Bortezomib92.586.73.81.91.9

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)

The AUC-ss is the area under the plasma concentration time curve observed during steady state. (NCT01646021)
Timeframe: Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)

Interventionnanogram*hour per milliliter (ng*h/mL) (Mean)
Ibrutinib561.6

Duration of Response

Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionMonths (Median)
Ibrutinib23.1
Temsirolimus6.3

Extent of Exposure of Time

Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment. (NCT01646021)
Timeframe: Approximately up to 46.8 months

InterventionMonths (Median)
Ibrutinib14.39
Temsirolimus3.02

Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months

InterventionEmergency room visits (Mean)
Ibrutinib1.2
Temsirolimus1.2

Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months

InterventionHospitalizations (Mean)
Ibrutinib3.1
Temsirolimus2.8

Number of Participants Affected With Treatment-emergent Adverse Events

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT01646021)
Timeframe: Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)

InterventionParticipants (Count of Participants)
Ibrutinib139
Temsirolimus138

Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib

Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy. (NCT01646021)
Timeframe: Approximately up to 28.2 months

InterventionParticipants (Number)
Ibrutinib61
Temsirolimus53

One Year Survival Rate

One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization. (NCT01646021)
Timeframe: Month 12

InterventionProportion of participants (Number)
Ibrutinib0.68
Temsirolimus0.61

Overall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionPercentage of participants (Number)
Ibrutinib77.0
Temsirolimus46.8

Overall Survival (OS)

Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionMonths (Median)
Ibrutinib30.3
Temsirolimus23.5

Progression Free Survival (PFS)

PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to [>=] 50 percent [%] of previously involved sites from nadir). (NCT01646021)
Timeframe: Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)

InterventionMonths (Median)
Ibrutinib15.6
Temsirolimus6.2

Progression-Free Survival 2

Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionMonths (Median)
Ibrutinib26.2
Temsirolimus15.4

Time to Response

Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response. (NCT01646021)
Timeframe: Approximately up to 2.8 years

InterventionMonths (Median)
Ibrutinib2.15
Temsirolimus2.14

Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionWeeks (Median)
IbrutinibNA
Temsirolimus10.6

Time-to-Next Treatment

Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment. (NCT01646021)
Timeframe: Approximately up to 48 months

InterventionMonths (Median)
Ibrutinib31.8
Temsirolimus11.6

Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months

,
InterventionDays (Mean)
Mean days of hospitalizationMean days of emergency room visits
Ibrutinib19.71.8
Temsirolimus20.31.6

The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment

The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state. (NCT01646021)
Timeframe: Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)

,
InterventionUnits on scale (Mean)
BaselineChange at Cycle 2Change at Cycle 3Change at Cycle 4Change at Cycle 5Change at Cycle 6Change at Cycle 7Change at Cycle 8Change at Cycle 11Change at Cycle 14Change at Cycle 17Change at Cycle 20Change at Cycle 28Change at Cycle 36Change at End of treatment
Ibrutinib0.70.00.10.00.00.10.00.00.00.00.00.0-0.10.00.0
Temsirolimus0.70.0-0.10.00.00.00.00.00.00.00.00.00.1-0.1-0.1

An Additional Endpoint Analysis Would Assess the MMT-8 Score in Patients With Muscle Disease as Measured at 3 and 6 Months Compared to Baseline.

"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

Interventionscore on a scale (Mean)
MMT-8 Score at 3 Months143.3
MMT-8 Score at 6 Months144.5

An Additional Secondary Endpoint Analysis Would Assess Quality of Life as Measured at 3 Months Compared to Quality of Life Measured at 6 Months

"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

Interventionscore on a scale (Mean)
DLQI Score at 3 Months6.3
DLQI Score at 6 Months4.2

An Additional Secondary Endpoint Analysis Would be Durability of Response Measured Participants CDASI Activity Score or Change in Their CDASI Activity Score at 6 Months Compared to 3 Months.

"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months

Interventionscore on a scale (Mean)
CDASI Score at 3 Months16.9
CDASI Score at 6 Months14

The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3 Months.

"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

InterventionParticipants (Count of Participants)
Dermatomyositis Patients With Refractory Cutaneous Disease7

2. The Secondary Endpoint Analysis Would be Safety as Measured by the Number of Participants Experiencing Adverse Events and Serious Adverse Events Occurring During 6 Months of Therapy and 1 Month Follow up.

"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months

InterventionParticipants (Count of Participants)
Headache Grade 1-2Nausea Grade 1-2Diarrhea Grade 1-2Herpes Zoster Grade 1-2Influenza Grade 1-2Pneumonia Grade 1-2Acute sinusitis Grade 1-2Hypertension Grade 1-2Ocular pressure Grade 1-2
Dermatomyositis Patients With Refractory Cutaneous Disease754211111

An Additional Endpoint is to Assess the Gene Expression Profiling and Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

,
InterventionChange (Number)
Down regulated genesUp regulated genes
Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling12372
Skin Biopsy at Baseline for Gene Expression Profiling00

An Additional Endpoint is to Assess the Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

,
InterventionPercentage of positive cell detection (Mean)
STAT1STAT3
Skin Biopsy at 3 Months Into Apremilast Therapy for IHC50.117.4
Skin Biopsy at Baseline for IHC96.244.3

Reviews

39 reviews available for adenine and Lymphoma, Mantle-Cell

ArticleYear
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
    Hematological oncology, 2022, Volume: 40, Issue:4

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle

2022
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Clinical therapeutics, 2019, Volume: 41, Issue:11

    Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell;

2019
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunothera

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    British journal of haematology, 2021, Volume: 193, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a

2021
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Drugs & aging, 2017, Volume: 34, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug Discovery; Graft vs Host Dis

2017
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidi

2018
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    British journal of haematology, 2017, Volume: 179, Issue:3

    Topics: Adenine; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines;

2017
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
    British journal of haematology, 2018, Volume: 181, Issue:3

    Topics: Adenine; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidin

2018
Novel therapies for relapsed/refractory mantle cell lymphoma.
    Best practice & research. Clinical haematology, 2018, Volume: 31, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell;

2018
Use of acalabrutinib in patients with mantle cell lymphoma.
    Expert review of hematology, 2018, Volume: 11, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lym

2018
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bridged Bicyclo Compounds, Heterocyclic; Clinical Tria

2018
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Current treatment options in oncology, 2018, 07-21, Volume: 19, Issue:9

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P

2018
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:5

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi

2019
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    PharmacoEconomics, 2019, Volume: 37, Issue:3

    Topics: Adenine; Adult; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lymphoma, Mantle-Cell; Piperid

2019
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    Drugs, 2018, Volume: 78, Issue:16

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug

2018
Lenalidomide for the treatment of mantle cell lymphoma.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:5

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans;

2019
Acalabrutinib for adults with mantle cell lymphoma.
    Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Hum

2019
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
    Science signaling, 2019, 02-05, Volume: 12, Issue:567

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Humans; Lymphoma, Mantle-Cel

2019
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    PloS one, 2019, Volume: 14, Issue:2

    Topics: Adenine; Atrial Fibrillation; Databases, Factual; Humans; Hypertension; Leukemia, Lymphocytic, Chron

2019
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic

2019
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
    Leukemia & lymphoma, 2013, Volume: 54, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; B-Lymphocytes; Drug Eval

2013
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic,

2014
Ibrutinib: first global approval.
    Drugs, 2014, Volume: 74, Issue:2

    Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular

2014
Ibrutinib in B-cell Lymphomas.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin

2014
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lympho

2014
Ibrutinib for the treatment of mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-01, Volume: 20, Issue:21

    Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lymp

2014
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human

2016
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Drugs, 2015, Volume: 75, Issue:7

    Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To

2015
Targets for Ibrutinib Beyond B Cell Malignancies.
    Scandinavian journal of immunology, 2015, Volume: 82, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho

2015
[Ibrutinib: A new drug of B-cell malignancies].
    Bulletin du cancer, 2015, Volume: 102, Issue:6 Suppl 1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53

2015
Ibrutinib in B lymphoid malignancies.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top

2015
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Annals of the New York Academy of Sciences, 2015, Volume: 1358

    Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph

2015
Treatment options for mantle cell lymphoma.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:16

    Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation;

2015
Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-10, Volume: 34, Issue:11

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch

2016
Ibrutinib for mantle cell lymphoma.
    Future oncology (London, England), 2016, Volume: 12, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combine

2016
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2016
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
    Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1

    Topics: Adenine; Aged; Aspirin; Diarrhea; Hemorrhage; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Staging;

2016
Targeting of B-cell receptor signalling in B-cell malignancies.
    Journal of internal medicine, 2017, Volume: 282, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans

2017

Trials

33 trials available for adenine and Lymphoma, Mantle-Cell

ArticleYear
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 01-01, Volume: 28, Issue:1

    Topics: Adenine; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Ac

2022
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Blood advances, 2022, 03-08, Volume: 6, Issue:5

    Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyc

2022
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Journal of hematology & oncology, 2021, 10-30, Volume: 14, Issue:1

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicycl

2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-10, Volume: 40, Issue:2

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma

2022
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-10, Volume: 40, Issue:2

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma

2022
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-10, Volume: 40, Issue:2

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma

2022
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-10, Volume: 40, Issue:2

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma

2022
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 04-10, Volume: 40, Issue:11

    Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Mantle-Cell;

2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    The Lancet. Oncology, 2022, Volume: 23, Issue:3

    Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxoru

2022
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Blood advances, 2022, 09-27, Volume: 6, Issue:18

    Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinaz

2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:7

    Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; M

2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    The New England journal of medicine, 2022, 06-30, Volume: 386, Issue:26

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease P

2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Leukemia, 2022, Volume: 36, Issue:10

    Topics: 3' Untranslated Regions; Adenine; Adult; Biological Factors; Humans; Lymphoma, Mantle-Cell; Neoplasm

2022
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
    British journal of haematology, 2020, Volume: 188, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma,

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    Pharmacology research & perspectives, 2020, Volume: 8, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace

2020
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Blood, 2021, 02-18, Volume: 137, Issue:7

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2021
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resist

2017
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Dec-01, Volume: 23, Issue:23

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Do

2017
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    British journal of haematology, 2017, Volume: 179, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose

2017
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    The Lancet. Haematology, 2018, Volume: 5, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia, 2018, Volume: 32, Issue:8

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; International Ag

2018
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    The New England journal of medicine, 2018, 03-29, Volume: 378, Issue:13

    Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineo

2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone marrow transplantation, 2019, Volume: 54, Issue:1

    Topics: Adenine; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoieti

2019
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    British journal of haematology, 2018, Volume: 182, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Ma

2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    The Lancet. Haematology, 2019, Volume: 6, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Heterocycl

2019
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    International journal of hematology, 2019, Volume: 109, Issue:3

    Topics: Adenine; Asian People; Female; Follow-Up Studies; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-C

2019
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood, 2019, 03-14, Volume: 133, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol

2019
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood, 2019, 03-14, Volume: 133, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol

2019
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood, 2019, 03-14, Volume: 133, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol

2019
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood, 2019, 03-14, Volume: 133, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol

2019
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Blood, 2013, Oct-03, Volume: 122, Issue:14

    Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell

2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Blood, 2013, Oct-03, Volume: 122, Issue:14

    Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell

2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Blood, 2013, Oct-03, Volume: 122, Issue:14

    Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell

2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Blood, 2013, Oct-03, Volume: 122, Issue:14

    Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell

2013
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio

2016
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Lancet (London, England), 2016, Feb-20, Volume: 387, Issue:10020

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp

2016
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Lancet (London, England), 2016, Feb-20, Volume: 387, Issue:10020

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp

2016
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Lancet (London, England), 2016, Feb-20, Volume: 387, Issue:10020

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp

2016
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Lancet (London, England), 2016, Feb-20, Volume: 387, Issue:10020

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp

2016
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Blood, 2016, 07-07, Volume: 128, Issue:1

    Topics: Adenine; Amino Acid Substitution; Apoptosis; Disease-Free Survival; Drug Resistance, Neoplasm; Femal

2016
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Cancer science, 2016, Volume: 107, Issue:12

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans;

2016

Other Studies

137 other studies available for adenine and Lymphoma, Mantle-Cell

ArticleYear
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
    Experimental hematology, 2021, Volume: 103

    Topics: Adenine; Animals; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; I-kappa

2021
Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2022, Volume: 31, Issue:3

    Topics: Adenine; Adult; Animals; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Mice; Piperidines;

2022
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:10

    Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Phosphat

2022
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
    International journal of hematology, 2022, Volume: 116, Issue:3

    Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Piperidines;

2022
SHINE a light: frontline ibrutinib for MCL.
    Nature reviews. Clinical oncology, 2022, Volume: 19, Issue:8

    Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Piperidines

2022
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
    Advances in therapy, 2022, Volume: 39, Issue:10

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans;

2022
Treatment of Mantle-Cell Lymphoma.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab

2022
Treatment of Mantle-Cell Lymphoma.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab

2022
Treatment of Mantle-Cell Lymphoma.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab

2022
Treatment of Mantle-Cell Lymphoma. Reply.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab

2022
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
    Terapevticheskii arkhiv, 2021, Jul-23, Volume: 93, Issue:7

    Topics: Adenine; Aged; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local;

2021
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
    Leukemia, 2023, Volume: 37, Issue:6

    Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Tumor Mi

2023
Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy.
    Internal medicine journal, 2019, Volume: 49, Issue:9

    Topics: Adenine; Aged; Antineoplastic Agents; Eye Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonan

2019
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Journal of immunology (Baltimore, Md. : 1950), 2019, 10-15, Volume: 203, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Re

2019
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
    Cancer medicine, 2019, Volume: 8, Issue:16

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Age

2019
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Cancer medicine, 2019, Volume: 8, Issue:17

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2019
Ibrutinib-Associated Reversible Cardiomyopathy.
    Journal of oncology practice, 2019, Volume: 15, Issue:12

    Topics: Adenine; Aged; Cardiomyopathies; Humans; Lymphoma, Mantle-Cell; Male; Mesentery; Piperidines; Pyrazo

2019
[Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:12

    Topics: Adenine; Aged; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Neoplas

2019
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
    European journal of haematology, 2020, Volume: 104, Issue:4

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bridged Bicy

2020
Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:6

    Topics: Adenine; Fatal Outcome; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Mantl

2020
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:7

    Topics: Adenine; Adult; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; SOXC Transcription Fac

2020
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
    British journal of haematology, 2021, Volume: 192, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ireland;

2021
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
    Journal of thrombosis and haemostasis : JTH, 2020, Volume: 18, Issue:10

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines;

2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome.
    Blood, 2020, 10-22, Volume: 136, Issue:17

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transdifferentiation; Cellular Reprogr

2020
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
    Annals of hematology, 2020, Volume: 99, Issue:11

    Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr

2020
Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.
    Journal of medical case reports, 2020, Aug-28, Volume: 14, Issue:1

    Topics: Adenine; Adult; Antigens, CD20; Enterovirus Infections; Humans; Lymphoma, Mantle-Cell; Middle Aged;

2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
    Blood advances, 2020, 10-13, Volume: 4, Issue:19

    Topics: Adenine; Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukocytes, Mononuclear; Lymphoma,

2020
Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.
    Balkan medical journal, 2021, Volume: 38, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; COVID-19; COVID-19 Drug Treatment; Follow-Up Studies; Humans;

2021
Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
    British journal of haematology, 2021, Volume: 192, Issue:4

    Topics: Adenine; Aged; Aged, 80 and over; Electronic Health Records; Female; Humans; Lymphoma, Mantle-Cell;

2021
Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:2

    Topics: Adenine; Aged; Diabetic Nephropathies; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Renal Dialy

2021
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:10

    Topics: Adenine; Aged; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Ce

2020
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
    Current research in translational medicine, 2021, Volume: 69, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Comorbidity; COVID-19; Humans; Lymphoma, Mantle-

2021
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Anticancer research, 2021, Volume: 41, Issue:2

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydro

2021
Building on BTK inhibition in MCL.
    Blood, 2021, 02-18, Volume: 137, Issue:7

    Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans;

2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    British journal of haematology, 2021, Volume: 193, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine

2021
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
    Cancer communications (London, England), 2021, Volume: 41, Issue:3

    Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Republic of

2021
Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
    Annals of hematology, 2021, Volume: 100, Issue:5

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocycl

2021
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
    International journal of molecular sciences, 2021, Feb-25, Volume: 22, Issue:5

    Topics: Adenine; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans;

2021
How should we use ibrutinib in patients with mantle cell lymphoma?
    British journal of haematology, 2021, Volume: 193, Issue:3

    Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines

2021
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
    Cell reports, 2021, 03-16, Volume: 34, Issue:11

    Topics: Adenine; Animals; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Resistance,

2021
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Cancer science, 2021, Volume: 112, Issue:6

    Topics: Adenine; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependen

2021
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Cancer science, 2021, Volume: 112, Issue:7

    Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fem

2021
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
    Pathology, 2021, Volume: 53, Issue:7

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp

2021
MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
    European journal of haematology, 2021, Volume: 107, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor

2021
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Clinical therapeutics, 2021, Volume: 43, Issue:8

    Topics: Adenine; Adult; Aged; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Patient Accept

2021
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-01, Volume: 23, Issue:15

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Dru

2017
Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    British journal of haematology, 2018, Volume: 181, Issue:4

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resis

2018
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
    Nature communications, 2017, 04-18, Volume: 8

    Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Hu

2017
Imbruvica
    British journal of nursing (Mark Allen Publishing), 2017, May-25, Volume: 26, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Le

2017
Pulmonary Cryptococcus Presenting as a Solitary Pulmonary Nodule.
    American journal of respiratory and critical care medicine, 2017, 11-01, Volume: 196, Issue:9

    Topics: Adenine; Aged; Cryptococcosis; Humans; Immunocompromised Host; Lung Diseases, Fungal; Lymphoma, Mant

2017
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
    JAMA oncology, 2018, Jan-01, Volume: 4, Issue:1

    Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell

2018
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:7

    Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging

2018
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica, 2018, Volume: 103, Issue:1

    Topics: Adenine; Bone Marrow; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Focal Adhe

2018
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
    Journal of hematology & oncology, 2017, 11-02, Volume: 10, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantl

2017
NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
    Blood cancer journal, 2017, 11-23, Volume: 7, Issue:12

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism

2017
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    British journal of haematology, 2019, Volume: 184, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di

2019
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Lymphoma, Mantle-Cell; Mice;

2018
Can we improve on ibrutinib in mantle cell lymphoma?
    The Lancet. Haematology, 2018, Volume: 5, Issue:3

    Topics: Adenine; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Grading; Piperidines; Pyr

2018
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
    Targeted oncology, 2018, Volume: 13, Issue:2

    Topics: Adenine; Cell Line, Tumor; Checkpoint Kinase 1; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein

2018
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:5

    Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Class

2018
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 08-16, Volume: 67, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu

2018
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
    British journal of haematology, 2018, Volume: 181, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female;

2018
Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:7

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation;

2018
Targeted combination has synergy in MCL.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:7

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazo

2018
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
    British journal of haematology, 2019, Volume: 185, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined C

2019
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Blood advances, 2018, 08-28, Volume: 2, Issue:16

    Topics: Adenine; Animals; Benzodioxoles; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP90 Heat-Shock Prote

2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    British journal of haematology, 2018, Volume: 183, Issue:4

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2018
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
    Oncogene, 2019, Volume: 38, Issue:11

    Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell

2019
Precision therapies take aim at non-Hodgkin's lymphoma.
    Nature, 2018, Volume: 563, Issue:7731

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Disease Models, Animal; Dogs; Drug Approval;

2018
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
    Haematologica, 2019, Volume: 104, Issue:5

    Topics: Adenine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Lymphoma, M

2019
[Mantle cell lymphoma of the iris treated by ibrutinib].
    Journal francais d'ophtalmologie, 2018, Volume: 41, Issue:10

    Topics: Adenine; Aged; Antineoplastic Agents; Humans; Iris; Iris Neoplasms; Lymphoma, Mantle-Cell; Male; Pip

2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
    Nature medicine, 2019, Volume: 25, Issue:1

    Topics: Activating Transcription Factor 3; Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic;

2019
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:12

    Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resist

2018
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
    Blood, 2019, 02-28, Volume: 133, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Hu

2019
Concurrent treatment with two B-cell receptor pathway inhibitors.
    The Lancet. Haematology, 2019, Volume: 6, Issue:1

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein

2019
Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:2

    Topics: Adenine; Antineoplastic Agents, Immunological; Gene Rearrangement; Humans; Lymphoma, Mantle-Cell; Ma

2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica, 2019, Volume: 104, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge

2019
Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
    American journal of respiratory and critical care medicine, 2019, 06-15, Volume: 199, Issue:12

    Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pip

2019
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
    Haematologica, 2019, Volume: 104, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biomarkers, Tumor; CD79 Antigen

2019
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
    Leukemia, 2019, Volume: 33, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Lymphoma, Large B-C

2019
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
    Molecular cancer research : MCR, 2019, Volume: 17, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzeneacetamides; Biomarkers, Tumor; Cell Line, Tumor

2019
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Leukemia, 2019, Volume: 33, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antigens, CD; Antigens, Differentiation, Myelomo

2019
The Muddied Waters of Ibrutinib Therapy.
    Acta haematologica, 2019, Volume: 141, Issue:4

    Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Male; Neuroaspergillosis; Piperidines; Pyrazoles; Pyr

2019
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
    Science translational medicine, 2019, 05-08, Volume: 11, Issue:491

    Topics: Adenine; Animals; Cell Line, Tumor; DNA Copy Number Variations; Drug Resistance, Neoplasm; Exome Seq

2019
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
    Scientific reports, 2019, 05-10, Volume: 9, Issue:1

    Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumo

2019
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:12

    Topics: Adenine; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Re

2019
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
    Haematologica, 2020, Volume: 105, Issue:2

    Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Py

2020
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
    The American journal of cardiology, 2019, 08-15, Volume: 124, Issue:4

    Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2019
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
    Expert review of clinical immunology, 2013, Volume: 9, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, Mantle-Cell; Neoplasm Prote

2013
Toward new treatments for mantle-cell lymphoma?
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidin

2013
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Leukemia research, 2013, Volume: 37, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Cell Line; Cell Survival; Gene Expression;

2013
Targeting the B-cell signalling pathway in CLL and MCL.
    The Lancet. Oncology, 2013, Volume: 14, Issue:9

    Topics: Adenine; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piper

2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
    Nature medicine, 2014, Volume: 20, Issue:1

    Topics: Adenine; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence; Blotting, Western; CARD Signali

2014
Ibrutinib approved for mantle cell lymphoma.
    Cancer discovery, 2014, Volume: 4, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Approval; Humans; Lymphoma

2014
Imbruvica--next big drug in B-cell cancer--approved by FDA.
    Nature biotechnology, 2014, Volume: 32, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Drug

2014
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    British journal of haematology, 2014, Volume: 166, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Pr

2014
Ibrutinib approved for the treatment of mantle cell lymphoma.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11, Issue:12

    Topics: Adenine; Drug Approval; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; United S

2013
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Cancer discovery, 2014, Volume: 4, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; Cell C

2014
A breakthrough in mantle cell lymphoma.
    The Johns Hopkins medical letter health after 50, 2014, Volume: 25, Issue:15

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Lymphoma, Mantle-Cell; Piperidines; Prot

2014
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
    Leukemia, 2015, Volume: 29, Issue:4

    Topics: Adenine; Adenosine Diphosphate; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cel

2015
Ibrutinib for the treatment of mantle cell lymphoma.
    Expert review of hematology, 2014, Volume: 7, Issue:5

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
    British journal of haematology, 2015, Volume: 168, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto

2015
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    International journal of cancer, 2015, Jun-15, Volume: 136, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Aminopyridines; Apoptosis; Bl

2015
Overcoming mantle cell lymphoma's ibrutinib resistance.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth

2014
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
    Blood, 2014, Dec-11, Volume: 124, Issue:25

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Animals, Newborn; Atrial Fibrillation; Gene E

2014
Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Adenine; Aged; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Mantle-Cell; Male; Piperidine

2015
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
    British journal of haematology, 2015, Volume: 170, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bone Marrow; Humans; Lymphocytosis; Lymphoma, Mantle-C

2015
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; bcl-X Protein; Bridg

2015
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
    Blood, 2015, Feb-05, Volume: 125, Issue:6

    Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochlo

2015
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
    Apoptosis : an international journal on programmed cell death, 2015, Volume: 20, Issue:7

    Topics: Adenine; Apoptosis; Caspases; Cell Line, Tumor; Cyclin D1; Drug Synergism; Histone Deacetylase Inhib

2015
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
    Blood, 2015, Apr-02, Volume: 125, Issue:14

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting,

2015
CCMCL1: a new model of aggressive mantle cell lymphoma.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Proto

2015
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neopla

2015
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
    Blood, 2015, Oct-01, Volume: 126, Issue:14

    Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Ma

2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Blood, 2015, Sep-24, Volume: 126, Issue:13

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Azepines; Cell Cycle P

2015
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16

    Topics: Adenine; Aged; Clinical Trials as Topic; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chron

2015
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
    Anticancer research, 2015, Volume: 35, Issue:12

    Topics: Adenine; Bendamustine Hydrochloride; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Piperidines;

2015
Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?
    Lancet (London, England), 2016, Feb-20, Volume: 387, Issue:10020

    Topics: Adenine; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles;

2016
Postibrutinib outcomes in patients with mantle cell lymphoma.
    Blood, 2016, Mar-24, Volume: 127, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease Progression; Female;

2016
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:1

    Topics: Adenine; Aged; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Di

2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Comb

2016
[Ibrutinib prescription in B-cell lymphoid neoplasms].
    Bulletin du cancer, 2016, Volume: 103, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistan

2016
Targeting protein kinase C in mantle cell lymphoma.
    British journal of haematology, 2016, Volume: 173, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Death; Drug Resistance, Ne

2016
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:3

    Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Protein Kina

2017
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:12

    Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Incidence;

2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17;

2016
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    British journal of haematology, 2017, Volume: 178, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Central

2017
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
    Oncotarget, 2016, Jun-21, Volume: 7, Issue:25

    Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylat

2016
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
    Oncotarget, 2016, Nov-08, Volume: 7, Issue:45

    Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Resistan

2016
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Blood, 2016, 11-24, Volume: 128, Issue:21

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Animals; Cell Line, Tumor; Dr

2016
Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas.
    World neurosurgery, 2017, Volume: 99

    Topics: Adenine; Aged; Antineoplastic Agents; Brain Neoplasms; Diagnosis, Differential; Hematoma, Subdural;

2017
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
    Hematological oncology, 2017, Volume: 35, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; P

2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Nature, 2017, 02-23, Volume: 542, Issue:7642

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Li

2017
Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Annals of hematology, 2017, Volume: 96, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Delayed Diagnosis; Diseas

2017
Novel targeted therapies for mantle cell lymphoma.
    Oncotarget, 2012, Volume: 3, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antigens

2012
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    British journal of haematology, 2013, Volume: 161, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto

2013